Persbericht: Programma bekend van gebruikersevent GiLab Commit 2019
Amsterdam — 30 augustus 2019 — GitLab, het DevOps platform,... Lees verder →
DARMSTADT, Germany, February 26, 2018 /PRNewswire/ -- Not intended for U.K./U.S. based media - First oral short-course treatment for highly active relapsing ...
Lees verderDARMSTADT, Germany, December 7, 2017 /PRNewswire/ -- Not intended for U.K./U.S. based media - First treatment in relapsing-remitting multiple sclerosis (RRMS) to ...
Lees verderDARMSTADT, Germany, December 4, 2017 /PRNewswire/ -- - First oral short-course treatment for relapsing- remitting multiple sclerosis (RRMS) now approved in ...
Lees verderDARMSTADT, Germany, August 25, 2017 /PRNewswire/ -- - First oral short-course treatment for highly active relapsing multiple sclerosis (RMS) now approved in ...
Lees verderDARMSTADT, Germany, June 26, 2017 /PRNewswire/ -- - Data suggest that MAVENCLAD(TM) (Cladribine Tablets) selectively and discontinuously reduces B and T ...
Lees verderDARMSTADT, Germany, June 23, 2017 /PRNewswire/ -- - Efficacy and safety data support positive benefit/risk assessment from CHMP - Cladribine Tablets is the ...
Lees verderDARMSTADT, Germany, June 24, 2017 /PRNewswire/ -- - New data builds on company's longstanding commitment to MS Merck, a leading science and technology company, ...
Lees verder